Henrietta Lacks

Henrietta Lacks built a foundation for modern cell biology and biomedicine through the extraordinary properties of the cancer cells taken from her body, which became the first widely used immortal human cell line known as HeLa. Her cellular legacy is central to vaccines, cancer therapies, reproductive medicine, and biomedical techniques that transformed global health, even as the dominant record long treated those cells as a laboratory resource rather than the work of a specific Black woman and her family. ## Life, community, and cellular authorship Henrietta Lacks was a Black tobacco farmer and mother from Clover, Virginia, who migrated with her family into the steel-town Black community around Turner Station in Baltimore County, part of the wider movement of Black southerners building industrial working-class neighborhoods in the mid‑20th century. In 1951, at Johns Hopkins Hospital—one of the few institutions that admitted Black patients in segregated Baltimore—doctors took tissue from a cervical tumor during treatment and passed those cells to researcher George Gey, who found that they reproduced indefinitely in culture. What researchers named “HeLa” was not an abstract resource; it was the living cellular material of Lacks’s own body, carrying her DNA into laboratories worldwide and anchoring an entire experimental infrastructure built atop an unconsented extraction from a Black patient. ## What HeLa cells built in medicine HeLa cells were used to help develop the polio vaccine, proving essential in mass‑screening of vaccine candidates and scaling up virus production, and later became standard tools for studying cancer biology, virology, radiation effects, toxicology, and human genetics. They underpinned breakthroughs in in‑vitro fertilization techniques, gene mapping and cloning methods, and the testing of drugs and cosmetics, becoming embedded in both commercial and academic research systems. The archive holds that every scientific narrative that lists “HeLa” among the tools of the lab without naming Henrietta Lacks as the human author of that cellular resource participates in a minimization that abstracts Black bodily contribution into anonymous infrastructure. ## Family testimony and Black archival remembrance For decades, Lacks’s family learned fragments of the story not from doctors or formal consent processes but from stray encounters with researchers and reporters, then began telling their own account of what had been done with her cells and what that meant for their faith, health, and sense of ownership. Black church and community spaces around Turner Station, including funeral programs and oral histories, preserved a memory of Henrietta Lacks as a mother and community member whose body had been taken into the medical system in ways that did not match the official story of lifesaving progress. Testimony from her children and relatives—about confusion, exploitation, and later activism—stands in this archive as evidence on its own terms, not as a mere supplement to institutional ethics reports. ## Policy, ethics, and the unequal terms of medical progress The use of Lacks’s cells occurred under Jim Crow medical conditions in which Black patients routinely received segregated care, limited information, and little formal recourse over their biological materials, while universities and companies accumulated patents, profits, and prestige from derivative technologies. Only decades later did bioethics literature begin using HeLa as a case study in informed consent, tissue ownership, and racial inequality, yet even those discussions often foregrounded policy debates over the specific injustice done to Lacks and her family. The archive holds that the medical and legal systems that denied Lacks recognition, consent, and control at the outset are part of the mechanism that routed scientific credit to laboratories and corporations rather than to the Black woman whose cells made their work possible. ## Ongoing recognition, reparative efforts, and contested credit In recent years, memorials, scholarships, and legal actions brought by Lacks’s descendants have forced institutions and companies to name her, pay settlements, and publicly acknowledge dependence on HeLa, moving her from the margins of scientific footnotes toward a recognized authorship in the story of modern medicine. Yet the standard telling still credits individual white scientists and research centers for specific breakthroughs built on HeLa, treating the cell line as a neutral tool rather than as a continuing embodiment of Lacks’s involuntary contribution. The archive holds this credit as still open and contested: the infrastructure of global biomedicine itself bears Henrietta Lacks’s imprint, and every acknowledgement that arrives decades late is a measure of how long the dominant record kept a Black woman’s authorship out of view.

1.Origins of HeLa and the making of an immortal cell line

Henrietta Lacks entered Johns Hopkins Hospital in Baltimore in early 1951 for treatment of cervical cancer, at a time when the institution’s “colored ward” was one of the few spaces where Black patients could access advanced care in a segregated city.

During a clinical procedure, doctors removed samples of her tumor and provided them to laboratory researcher George Gey, who had been seeking cells that could be sustained in vitro for extended experimentation. Unlike prior samples, Lacks’s cells divided rapidly and continuously, allowing Gey to establish what became known as an immortal human cell line.

He labeled the culture “HeLa,” compressing Lacks’s name into a laboratory code and separating the identity of the cell line from the person, a move that made it easy for later accounts to treat HeLa as an object rather than as the work of a specific Black woman.

2.What medicine built atop HeLa

Once established, HeLa cells were distributed to laboratories around the world and soon became crucial to Jonas Salk’s and Albert Sabin’s efforts to develop and test polio vaccines, enabling large‑scale virus production and controlled trials that would have been far more difficult without a reliable human cell line.

In subsequent decades, HeLa became a standard tool in oncology research, used to study cancer cell behavior, chromosome abnormalities, and the effects of radiation and chemotherapeutic agents, shaping clinical practice and drug development.

The cells were pivotal in early human genetics and molecular biology, including the development of techniques for culturing cells, mapping genes, and manipulating DNA in ways that laid groundwork for later biotechnology and pharmaceutical industries. Commercial firms profited from selling HeLa and HeLa‑derived products, while Lacks’s family received no recognition or share of that value.

3.Black community narratives and the politics of knowledge

For years after Henrietta Lacks’s death, her family remained largely uninformed about how her cells were being used, learning only in the 1970s that HeLa was widespread in labs when researchers approached them for blood samples to help distinguish HeLa contamination from other cultures.

Oral history interviews with her children and relatives—later collected in Black press coverage and works like Rebecca Skloot’s “The Immortal Life of Henrietta Lacks”—document their shock, anger, and spiritual wrestling with the idea that their mother’s cells lived on in countless experiments, unknown to them and uncredited.

Within Black communities in Baltimore and beyond, Lacks’s story became a touchstone for discussions of medical mistrust, bodily autonomy, and the long history of experiments on Black patients, often framed alongside accounts of hospital segregation and unethical studies.

4.Law, ethics, and structural exclusion from credit

When Lacks’s tissue was taken and used, there was no requirement for specific informed consent for tissue use in research, and property law treated excised tissue as belonging to the institution or researcher, not to the patient. This legal framework effectively erased patient ownership and made it easy for institutions to claim full control over biological materials.

Because Black patients like Lacks entered medicine under conditions of segregated care and social inequality, they faced particular vulnerability to having their bodies used for research without explanation or meaningful recourse, a pattern echoed in subsequent cases of unethical experimentation.

Biomedical ethics debates later used HeLa as a case study in informed consent and tissue property, but these discussions often focused on abstract principles rather than on the racialized power relations that shaped whose bodies were taken and whose names appeared on the resulting publications and patents.

5.Correcting the record: memorials, litigation, and authorship

In the early twenty‑first century, renewed attention to HeLa and Lacks’s story led to formal recognition: plaques, scholarships, and public commemorations at Johns Hopkins and in Baltimore; family participation in advisory boards; and legal actions by her descendants against companies that had profited from HeLa‑based products.

Settlements and public statements have begun to frame Henrietta Lacks as an essential figure in medical history, and agreements have sometimes promised family input and benefit‑sharing, signaling a partial shift from viewing HeLa as an ownerless tool to viewing it as a legacy with identifiable heirs.

The archive, however, notes that scientific papers and textbooks still largely credit named researchers and institutions for specific discoveries built on HeLa, leaving Lacks’s authorship in the background. Until the routine naming of HeLa is paired with explicit recognition of Henrietta Lacks herself as a co‑author of modern cell culture, the record of who built this biomedical infrastructure remains incomplete.

The family archive is admissible here. Photographs, letters, deeds, church programs, funeral bulletins, business records, recordings — the things that were kept when no institution was keeping them. A keeper reviews everything before it is admitted, and your name stays on it.

7.References